AbbVie Reports ELAHERE Phase 3 Success for Ovarian Cancer

AbbVie has reported favorable results from the MIRASOL trial of ELAHERE, indicating significant improvements for women with platinum-resistant ovarian cancer, which has contributed to a 23% rise in the company's share price. Despite this positive momentum, AbbVie faced a net loss in the last quarter, although its generous cash dividend may have bolstered investor confidence. In related developments, new data from the KEYLINK-001 trial revealed that the combination of pembrolizumab and olaparib significantly improved progression-free survival in patients with advanced BRCA non-mutated ovarian cancer. Conversely, a phase 2 trial of afuresertib combined with paclitaxel did not demonstrate a significant survival advantage, although it maintained a manageable toxicity profile. Furthermore, Sutro Biopharma presented promising data on luveltamab tazevibulin, highlighting its antitumor activity in platinum-resistant ovarian cancer. These advancements reflect ongoing efforts to improve treatment options for ovarian cancer patients amid a competitive landscape.